Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tacti-002 save search
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: -1.72%
tacti-004 lung cancer cell trial
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 1.1%
H: 0.54%
C: -3.26%
tacti-003 keytruda cell trial
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 2.15%
H: 1.05%
C: 0.0%
tacti-002 lung biomarker cancer cell
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 15:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 3.01%
H: 1.89%
C: -4.09%
tacti-002 presentation asco meeting
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Published: 2023-01-04 (Crawled : 15:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -1.64%
H: 7.22%
C: 5.0%
tacti-003 trial cancer milestone
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.0%
H: 3.74%
C: 3.21%
tacti-003 trial positive
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 1.41%
H: 3.7%
C: -0.93%
tacti-002 conference cancer
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
Published: 2022-06-02 (Crawled : 19:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 2.7%
H: 1.32%
C: -0.66%
tacti-002 asco
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Published: 2022-05-27 (Crawled : 12:20) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -1.81%
H: 10.85%
C: 7.72%
tacti-002 asco publication
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Published: 2022-04-28 (Crawled : 20:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.91%
H: 11.27%
C: 8.6%
tacti-002 presentation asco
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
Published: 2022-03-24 (Crawled : 20:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.43%
H: 1.56%
C: -2.81%
tacti-002 cancer
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Published: 2022-02-18 (Crawled : 13:30) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.79%
H: 2.29%
C: 1.19%
tacti-002 europe lung cancer cancer
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
Published: 2021-11-19 (Crawled : 13:30) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -0.51%
H: 1.82%
C: -1.55%
therapy
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.47%
H: 1.16%
C: -0.93%
positive therapy trial
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 5.26%
H: 0.0%
C: -25.6%
Immutep to Present Phase II TACTI-002 Data at SITC 2021
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.52%
H: 0.77%
C: -0.51%
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Published: 2021-09-01 (Crawled : 14:15) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -2.63%
H: 1.16%
C: -1.42%
Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting
Published: 2021-05-20 (Crawled : 14:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 11.65%
H: 10.0%
C: 3.7%
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Published: 2021-04-28 (Crawled : 15:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 0.3%
H: 2.84%
C: 0.6%
presentation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.